AN2 Therapeutics, Inc. (ANTX) Análise de ações

Visão geral da empresa

A biopharmaceutical enterprise, AN2 Therapeutics, Inc. is dedicated to the discovery and development of novel small molecule therapeutics designed to address specific medical conditions. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself to leverage the regulatory pathways and scientific advancements specific to drug development. According to the available data, the entity employs a workforce of 21 individuals and holds a market capitalization of $109.62 million. These figures indicate a company currently in an early-stage or pre-revenue phase, where the market cap reflects investor sentiment regarding future pipeline potential rather than established annual revenue streams or profitability.

Saúde financeira

The financial performance metrics for the trailing twelve months (TTM) show N/A for revenue and N/A for EBITDA, while the reported net income stands at -$35,174,000. The absence of recorded revenue alongside significant net losses reveals a cost structure dominated by research, development, and operational expenses necessary to advance clinical candidates such as epetraborole. The company reported a free cash flow of -$18,382,124, which signifies a net outflow of cash required to fund ongoing operations and clinical trials without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a standard characteristic for pre-revenue biotechnology firms where no sales have been generated to calculate profitability percentages. In terms of liquidity and solvency, the company holds $58.00 million in cash against $0 in debt, creating a conservative balance sheet with no leverage obligations. The current ratio is listed at 6.87, indicating that the company possesses 6.87 times the current assets necessary to cover its current liabilities, suggesting robust short-term liquidity despite the lack of sales. Furthermore, the return on equity (ROE) is -52.1% and the return on assets (ROA) is -30.9%, metrics that reflect the dilution of equity and assets due to accumulated net losses rather than management effectiveness in generating profit from existing capital.

Avaliação de valorização

The valuation profile includes a P/E ratio (TTM) of N/A and a forward P/E of -3.81, the latter of which implies that the market is pricing the stock based on negative expected earnings or a specific methodology for pre-profitability firms. The price-to-book ratio is 1.58, indicating that the market values the company at 1.58 times its book value, which may reflect the intrinsic value of the company's intangible assets and pipeline potential rather than current earnings power. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional multiple-based comparisons are not applicable given the lack of sales data and the negative earnings environment. The stock has traded within a 52-week range between a high of $6.91 and a low of $1.00, with the current price position relative to this range dependent on real-time market data not provided in the static facts. The beta value is recorded as -1.32, a negative coefficient that suggests the stock's price movements have historically moved inversely to the broader market, presenting a unique volatility profile distinct from standard equities.

Growth & Income

The growth metrics for revenue and earnings over the last year are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical year-over-year growth rates cannot be calculated from sales data. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A or 0.0%, respectively, meaning the firm retains all available cash flow to reinvest into its drug discovery pipeline and clinical trial programs rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete reliance on capital raising and internal cash reserves to fund expansion, with no current income generation or historical growth trajectory to analyze against revenue benchmarks.